GlassScriptPhysician profile
John D Andress
NPI 1598746083
$3,249.96
in general payments reported to CMS, 2019-2025
27 companies · $44.28 in 2025
The $44.28 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,489 · 2020: $214 · 2021: $210 · 2022: $824 · 2023: $453 · 2024: $15.60 · 2025: $44.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $512.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $483.33 | 2019-2025 | Watchman Access System, Watchman Flx, Farapulse |
| Preventric Diagnostics, INC. | $370.22 | 2022 | |
| Janssen Pharmaceuticals, INC | $256.40 | 2019-2022 | |
| Amgen INC. | $253.01 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.72 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $194.19 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $190.75 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $189.35 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $169.27 | 2019-2021 | |
| Pfizer INC. | $138.04 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $135.64 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $111.75 | 2021-2022 | |
| Endologix LLC | $99.20 | 2022 | |
| Lantheus Medical Imaging, INC. | $79.22 | 2019 | |
| Medtronic Vascular, INC. | $72.25 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $43.90 | 2019 | |
| Gilead Sciences, INC. | $38.46 | 2019 | |
| Amarin Pharma, INC. | $37.58 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $35.84 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $24.16 | 2019 | |
| Vifor Pharma, INC. | $22.62 | 2019 | |
| Medtronic, INC. | $22.24 | 2023 | Micra |
| Edwards Lifesciences Corporation | $21.11 | 2022 | |
| Medtronic USA, INC. | $19.59 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $19.08 | 2022 | |
| Elutia, INC. | $13.11 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $12.93 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Andress listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.